CommentaryInflammation and Alzheimer’s disease
Introduction
A virtual textbook of inflammatory mediators has been observed in the Alzheimer’s disease (AD) brain over the last 15 years. These mediators are typically at undetectable or background levels in samples from nondemented elderly (ND) patients, and have been investigated at immunohistochemical, biochemical, and molecular levels. As with all new developments in science, perception of these findings has evolved over time. Initially, resistance was high. Many of the early results were dismissed as artifact, an impossibility given the “immunologic privilege” of the brain. This narrow view, however, gradually eroded thanks to seminal work in classical neuroimmunology [cf. 209,210,591,592] as well as a burgeoning literature confirming and extending the presence of inflammatory molecules in AD brain [for previous reviews, see 6,350,384,453,457]. It is now clear that the brain may have many unique immunologic properties, but it is by no means an immunologically isolated organ.
With this understanding, new challenges have arisen. Are inflammatory mechanisms actually causing damage in AD or are they present merely to remove the detritus from other, more primary pathologic processes? Are anti-inflammatory drugs a viable therapeutic option for AD? Such questions, too, are beginning to find answers. Direct and tangential evidence of a neurodegenerative role for AD inflammatory processes has been provided from basic research studies, and clinical research, although still inconclusive with respect to the best choice of an anti-inflammatory therapeutic, has widely suggested that conventional nonsteroidal anti-inflammatory drugs (NSAIDs) may delay the onset and slow the progression of AD [reviewed in 351].
Many misunderstandings and gaps in our knowledge about AD inflammation nonetheless persist. The fact that AD inflammation appears to arise from within the CNS, with little or no involvement of lymphocytes or monocytes beyond their normal surveillance of brain [591], has put it out of the realm of conventional neuroimmunologic studies that focus largely on humoral aspects of such CNS inflammatory disorders as multiple sclerosis. How and when inflammation arises in the course of AD has not yet been fully resolved, and for some the pathophysiologic significance of AD inflammation itself still remains an issue. Perhaps most of all, AD inflammation research has most often been compartmentalized, with some groups specializing in cytokines, others in complement, chemokines, growth factors, oxidative stress, microglial activation, astrocyte reactivity, or other areas. In fact, however, inflammatory mechanisms are highly interactive and almost never occur in isolation from each other.
For these reasons, a review that goes beyond the simple tabulation of AD inflammatory mediators may be timely. Here, we have attempted to martial the evidence for a pathophysiologically relevant role of AD inflammation and to take into account the myriad interactions of inflammatory mediators. By doing so, it may be possible to gain new insights into how inflammation fits into the overall framework of AD pathology as well as how best to design new therapeutics to combat AD inflammation.
Section snippets
Inflammatory pathways in the AD brain
From immunohistochemical, biochemical, and molecular studies of AD and ND postmortem tissue, and, in particular, by reference to known inflammatory pathways in the periphery, it has become tenable to attempt to organize the many inflammatory mediators uncovered in the AD brain into a working model (see enclosed poster). At its center are amyloid β peptide (Aβ), neurofibrillary tangles, and neuronal degeneration, the hallmarks of AD for nearly a century. Just as damaged tissue and the chronic
Microglia
Activated microglia cluster at sites of aggregated Aβ deposition and deeply interdigitate neuritic plaques. Because they are related to peripheral macrophages [97], [302], they are one of the most obvious targets for research in AD inflammation and, indeed, much of the early impetus for research into inflammatory processes in AD came from the discovery that, like activated peripheral macrophages, many of the microglia in pathologically vulnerable areas of the AD brain express major
Animal models of AD neuroinflammation
A novel animal model has been reported that uses chronic, low-dose infusion of the inflammogen LPS into the ventricular system. Several parallels with AD inflammation are observed in this model, including increased activation of microglia, astrogliosis, increased tissue levels of IL-1β and TNF-α, elevated APP induction, temporal lobe pathology associated with cell loss and microglial reactivity [195], [594], and a working memory deficit [195], [197], [198]. Magnetic resonance imaging studies
Inflammation as a cause of damage to the AD brain
Inflammation, whether in the brain or the periphery, is almost always a secondary response to some more primary pathogen. This does not mean, however, that it is unimportant. In head trauma, for example, the blow to the head is the primary event. What will typically concern the neurologist and neurosurgeon more, however, is the secondary inflammatory response that will ensue and likely cause more neuron loss than the initial injury. Thus, a secondary inflammatory response often comes to be as
Anti-inflammatory drug studies
As the previous sections establish, chronic, local inflammatory responses occur in pathologically vulnerable areas of the AD brain. These responses orchestrate numerous well-known phenomena in AD pathology such as microglial clustering at sites of Aβ deposition and exacerbate the damage done by other AD pathogenic factors. It follows, then, that anti-inflammatory therapy should be beneficial in delaying the onset or slowing the progression of AD. This hypothesis has been directly and indirectly
Future directions
One of the issues that has not achieved complete consensus among the multiple authors of this review concerns cytoprotective versus cytopathic actions of several inflammatory mediators, particularly TNF-α and the complement anaphylatoxins. On the one hand, the very name for TNF-α, tumor necrosis factor-α, much less its potent effects on angiogenesis and its potent ability to activate other destructive inflammatory mechanisms, makes it implausible that this cytokine would not, overall, exert
Conclusion
It is indisputable that neuroinflammation occurs in the AD cortex. Mechanisms that parallel those encountered in localized peripheral inflammatory responses are readily identified, along with detailed pathways for how the mechanisms interact. There are also obvious parallels in the AD brain to the conditions that stimulate localized peripheral inflammation: the chronic presence of highly insoluble deposits of abnormal proteins, as well as chronic damage to tissue. What is, in fact, surprising
Acknowledgements
We are grateful to Parke–Davis Pharmaceuticals for their continuing support of the Neuroinflammation Working Group and the development of this manuscript.[3], [6], [100], [130], [162], [199], [204], [209], [210], [223], [304], [333], [360], [381], [383], [385], [403], [453], [457], [513], [517], [562], [592], [606], [612]
References (635)
- et al.
Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer’s disease
Cell
(1988) - et al.
Localization and cell association of C1q in Alzheimer’s disease brain
Exp Neurol
(1996) - et al.
IL-6 in biology and medicine
Adv Immunol
(1993) - et al.
Thrombin accumulation in brains of patients with Alzheimer’s disease
Neurosci Lett
(1992) - et al.
Immunohistochemical localization of vitronectin, its receptor and beta-3 integrin in Alzheimer brain tissue
J Neuroimmunol
(1991) - et al.
Immunohistochemical detection of coagulation factor XIIIa in postmortem human brain tissue
Neurosci Lett
(1995) - et al.
Brain microglia constitutively express beta-2 integrins
J Neuroimmunol
(1990) - et al.
Histochemical detection of 4-hydroxynonenal protein in Alzheimer amyloid
J Neurol Sci
(1998) - et al.
Trophic effect of beta-amyloid precursor protein on cerebral cortical neurons in culture
Biochem Biophys Res Commun
(1991) - et al.
Chemokines in the CNSplurifunctional mediators in diverse states
Trends Neurosci
(1999)
The NF-kappaB/Rel family of proteins mediates Abeta-induced neurotoxicity and glial activation
Mol Brain Res
Effects of IL-1 and IL-6 on metallothionein and amyloid precursor protein expression in human neuroblastoma cells
Evidence that IL-6 possibly acts via a receptor different from the 80-kDa IL-6 receptor. J Neuroimmunol
In-vitro matured human macrophages express Alzheimer’s beta A4-amyloid precursor protein indicating synthesis in microglial cells
FEBS Lett
IL-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer’s disease cortices
FEBS Lett
Rheumatoid arthritis and susceptibility to Alzheimer’s disease
Lancet
The polymorphism in exon 3 of the low density lipoprotein receptor- related protein gene is weakly associated with Alzheimer’s disease
Neurosci Lett
Alzheimer’s disease, and oxidative stress. Implications for novel therapeutic approaches
Prog Neurobiol
Evidence for an early inflammatory response in the central nervous system of mice with scrapie
Neuroscience
β-amyloid peptide secretion by a microglial cell line is induced by b-amyloid (25–35) and lipopolysaccharide
J Biol Chem
Cholinergic neurotransmission has different effects on cerebral glucose consumption and blood flow in young normals, aged normals, and Alzheimer’s disease patients
Neuroimage
NSAIDS inhibit the IL-1 beta-induced IL-6 release from human post-mortem astrocytesthe involvement of prostaglandin E2
Brain Res
Effects of IL-1 receptor antagonist on the behavioral effects of lipopolysaccharide in rat
Brain Res
MRI of entorhinal cortex in mild Alzheimer’s disease
Lancet
TGF-beta in kidney fibrosisa target for gene therapy
Kidney Int
Delayed onset of Alzheimer’s disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs
Neurobiol Aging
Anti-death properties of TNF against metabolic poisoningmitochondrial stabilization by MnSOD
J Neuroimmunol
Evidence that TNF alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor
J Biol Chem
Adult neurogenesis is regulated by adrenal steroids in the dentate gyrus
Neuroscience
Transgenic mice and cytokine actions in the brainbridging the gap between structural and functional neuropathology
Brain Res Rev
Neuroglial-mediated immunoinflammatory responses in Alzheimer’s diseasecomplement activation and therapeutic approaches
Neurobiol Aging
Effect of a carboxy-terminal fragment of the Alzheimer’s amyloid precursor protein on expression of proinflammatory cytokines in rat glial cells
Life Sci
Glycoprotein 330/megalin (LRP-2) has low prevalence as mRNA and protein in brain microvessels and choroid plexus
Exp Neurol
Production of superoxide anions by a CNS macrophage, the microglia
FEBS Lett
β-amyloid converts an acute phase injury response to chronic injury response
Neurobiol Aging
The alpha-2 macroglobulin gene is not associated with Alzheimer’s disease in a case-control sample
Neurosci Lett
Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response
J Biol Chem
Glial cell-specific mechanisms of TGF-beta 1 induction by IL-1 in cerebral cortex
J Neuroimmunol
Cellular forms and functions of brain microglia
Brain Res Bull
The amyloid beta-protein of Alzheimer’s disease is chemotactic for mononuclear phagocytes
Biochem Biophys Res Commun
Nitric oxide neurotoxicity
J Chem Neuroanat
TrkA immunoreactivity in reactive astrocytes in human neurodegenerative diseases and colchicine-treated rats
Acta Neuropathol (Berlin)
Inflammatory mechanisms in Alzheimer’s diseaseimplications for therapy
Am J Psychiatry
Glucocorticoids in Alzheimer’s disease. The story so far
Drugs Aging
Astrocyte-specific but not neuron-specific transmembrane TNF triggers inflammation and degeneration in the central nervous system of transgenic mice
J Immunol
Expression of intercellular adhesion molecule (ICAM)-1 by a subset of astrocytes in Alzheimer disease and some other degenerative neurological disorders
Acta Neuropathol (Berlin)
Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration
J Immunol
Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer’s disease? The Rotterdam Study
Neurology
The myeloperoxidase system of human phagocytes generates nepsilon-(carboxymethyl) lysine on proteinsa mechanism for producing advanced glycation end products at sites of inflammation
J Clin Invest
Cited by (3923)
GDI2 deletion alleviates neurodegeneration and memory loss in the 5xFAD mice model of Alzheimer's disease
2024, Biochimica et Biophysica Acta - Molecular Basis of DiseaseAdherence to the MIND diet and the odds of mild cognitive impairment in generally healthy older adults: The 3-year DO-HEALTH study
2024, Journal of Nutrition, Health and AgingDoes gut brain axis has an impact on Parkinson's disease (PD)?
2024, Ageing Research Reviews